Authors
Filimonov V.B.1, 3, Vasin R.V.2, 3, Sobennikov I.S.2, 3, Shirobakina E.Yu.3
1 State Ambulance hospital, Ryazan
2 City Clinical Hospital №11, Ryazan
3 Ryazan state medical university named after acad. I.P. Pavlov, Ryazan
Abstract
This literature review presents the results of recent studies on drugs used in the treatment of lower urinary tract symptoms in benign prostatic hyperplasia, as well as the mechanisms of the emergence of resistance to therapy of this disease.
Keywords: benign prostatic hyperplasia, conservative treatment of benign prostatic hyperplasia, lower urinary tract symptoms, acute urinary retention, alpha-blockers, 5-alpha reductase inhibitors, M-anticholinergics, type 5 phosphodiesterase inhibitors.
References
1. Speakman M, Kirby R, Doyle S, Ioannou C. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) — focus on the UK. BJU Int. 2015; 115: 508–19. doi: 10.1111/bju.12745.
2. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N’dow J, Nordling J, de la Rosette JJ. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur. Urol. 2013; 64(1): 118–140.
3. Borisov VV. Combined therapy with an α1-adrenergic blocker and a phosphodiesterase type 5 inhibitor in patients with benign prostatic hyperplasia and erectile dysfunction: results of an observational prospective multicenter study. Urology. 2020; 3: 50–55. doi: 10.18565/urology.2020.3.50-55.
4. Hisasue S, Furuya R, Itoh N, et al. Ejaculatory disorder caused by alpha-1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission. Int J Urol. 2006; 13(10): 1311–6.
5. Mondul Alison M, Rimm Eric B, Giovannucci Edward, et al. A Prospective Study of Lower Urinary Tract Symptoms and Erectile Dysfunction. J Urol. 2008; 179(6): 2321–2326. doi:10.1016/j. juro.2008.01.150.
6. Pande S, Hazra A, Kundu AK. Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: a randomized controlled trial. Indian J. Pharmacol. 2014; 46(6): 601–607.
7. Hisasue S, Furuya R, Itoh N, et al. Ejaculatory disorder caused by alpha-1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission. Int J Urol. 2006; 13(10): 1311-6.
8. Descazeaud A, de La Taille A, Giuliano F, et al. Negative effects on sexual function of medications for the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prog. Urol. 2015; 25(3): 115–127.
9. Kim BS, Kim T-H, Ko YH. Prostatic urethral length as a predicting factor for medical treatment failure of benign prostatic hyperplasia: Prospective, multi-center study. Eur. Urol. Suppl. 2015; 14 (2): 361.
10. Perugia C, Miano R, Topazio L. Intravesical prostatic protrusion influences the efficacy of alpha-blockers in men with lower urinary tract symptoms (LUTS) and benign prostatic enlargement (BPE). Eur. Urol. Suppl. 2015; 14 (2): 680.
11. Ergakov DV, Martov AG. Modern view of the conservative therapy of lower urinary tract symptoms in men. Urology. 2015; 5: 97–103. (In Russ).
12. Ken-ichi M., Mizoguchi S., Sumino Y., Sato F. Effects of dutasteride on bone mineral density and hematogenesis in patients with benign prostatic hyperplasia. Eur. Urol. Suppl. 2015; 14(2): 687.
13. Busetto GM, Giovannone R, Antonini G, et al. Short-term pretreatment with a dual 5α-reductase inhibitor before bipolar transurethral resection of the prostate (B-TURP): Evaluation of prostate vascularity and decreased surgical blood loss in large prostate. Eur. Urol. Suppl. 2015; 14 (2): 678.
14. Zhu YP, Dai B, Zhang HL, et al. Impact of preoperative 5α-reductase inhibitors on perioperative blood loss in patients with benign prostatic hyperplasia: a meta-analysis of randomized controlled trials. BMC Urol. 2015; 15(1): 47.
15. Sakalis V, Sfiggas V, Vouros I. Is there an effect of antimuscarinics on the prostate? Preliminary results from a randomized study in patients with benign prostate enlargement (BPE) and overactive bladder (OAB). Eur. Urol. Suppl. 2015; 14 (2): 686.
16. Huang EY-H, Lin C-C, Chung H-J, et al. Urinary retention following antimuscarinics in patients with BPH in real life practice — a nation-wide database study. American Urological Association Annual Meeting; San Diego, CA; May 4–8, 2013. Abstr 1386.
17. Park KK, Lee SH, Chung BH, Kim SJ, Kwak C, Son HC, Kim SW, Lee JY. Efficacy and safety of low-dose anticholinergics to treat men with lower urinary tract symptoms with overactive bladder: a retrospective study based on real life practice. Prostate Int. 2013; 1(1): 37–41.
18. Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. J Am Med Assoc. 2006; 296: 2319–28. doi: 10.1001/jama.296.19.231.
19. Kalinina SN, Koren’kov DG, Fesenko VN. Diagnosis and treatment of erectile dysfunction in patients with benign prostatic hyperplasia. Urologicheskie vedomosti. 2017; 7: 43–44. (Special issue: Proceedings of the 3rd scientific and practical conference of urologists of the North-West Federal District of the Russian Federation; Sankt-Peterburg, April 20–21, 2017.). (In Russ).
20. Brock GB, McVary KT, Roehrborn CG, et al. Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies. J Urol. 2014; 191: 405–11. doi: 10.1016/j.juro.2013.09. 057.
21. Stief CG, Porst H, Neuser D, et al. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2008; 53: 1236–44. doi: 10.1016/j.eururo.2008.01.075.
22. Kruep EJ, Hogue SL, Eaddy MT, et al. Clinical and economic impact of early versus delayed 5-alpha reductase inhibitor therapy in men taking alpha blockers for symptomatic benign prostatic hyperplasia. PT. 2011; 36(8): 493–50.
23. Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Curr Urol Rep. 2019; 20: 40. Eur Urol. 2010; 57: 123–31. doi: 10.1016/j.eururo.2009. 09.035.
24. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003; 349: 2387–98. doi: 10.1056/NEJMoa030656.
25. Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Curr Urol Rep. 2019; 20: 40. Eur Urol. 2010; 57: 123–31. doi: 10.1016/j.eururo.2009. 09.035.
26. Gul ZG, Kaplan SA. BPH: Why Do Patients Fail Medical Therapy? Curr Urol Rep. 2019; 20(7): 40. doi: 10.1007/s11934-019-0899-З. PMID: 31168725.
27. Sakr AMN, Fawzi AM, Youssef MK. Sildenafil in combination with tamsulosin versus tamsulosin monotherapy for management of male lower urinary tract symptoms due to benign prostatic hyperplasia: A randomized, double-blind trial. Eur. Urol. Suppl. 2015; 14(2): 683.
28. Roehrborn CG, Casabé A, Glina S, et al. Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo. Int. J. Urol. 2015; 22(6): 582–587.
29. Thomas K, Oades G, Taylor-Hay C, et al. Acute urinary retention: what is the impact on patients’ quality of life? BJU Int. 2005; 95(1): 72–76. doi: 10.1111/j.1464-410X.2004.05254.x.
30. Belyj LE, Solov’ev DA. Combined use of TWOC and a-blockers in the treatment of acute urinary retention in benign prostatic hyperplasia. Diagnostics and treatment of the most common human diseases. URL (In Russ).
31. Elhilali M, Vallancien G, Emberton M, et al. Management of acute urinary retention (AUR) in patients with BPH. A worldwide comparison. Eur Urology. 2004; 3(2): 59. doi: 10.1016/s1569-9056(04)90226-6.
32. Cindolo L, Pirozzi L, Fanizza C, et al. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study. Eur Urol. 2015; 68: 418–25. doi: 10.1016/j.eururo.2014.11. 006.
33. Shapiro E, Hartanto V, Lepor H. The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate. 1992; 21: 297–307. doi: 10.1002/pros.2990210406.
34. Kojima Y, Sasaki S, Kubota Y, et al. Expression of α1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective α1-adrenoceptor antagonists in the management of benign prostatic hyperplasia. J Urol. 2008; 179: 1040–6. doi: 10.1016/j.juro.2007.10.082.
35. Niu Y, Ge R, Hu L, et al. Reduced levels of 5-α reductase 2 in adult prostate tissue and implications for BPH therapy. Prostate. 2011. doi: 10.1002/pros.21348.
36. Bechis SK, Otsetov AG, Ge R, et al. Age and obesity promote methylation and suppression of 5αreductase 2: implications for personalized therapy of benign prostatic hyperplasia. J Urol. 2015; 194: 1031–7. doi: 10.1016/ j.juro.2015.04.079.
37. Kang PM, Kim YJ, Seo WT, et al. Correlation between 5-α reductase type 2 protein expression and methylation of 5-α reductase type 2 promotor gene of benign prostatic hyperplasia. World J Urol. 2018.
38. Mishra VC, Allen DJ, Nicolaou C, et al. Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? BJU Int. 2007; 100: 327–31. doi: 10.1111/j.1464-410X.2007. 06910.x.
39. Albisinni S, Biaou I, Marcelis Q, et al. New medical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia and future perspectives. BMC Urol. 2016; 16: 58. doi: 10.1186/s12894-016- 0176-0.
